282 related articles for article (PubMed ID: 15515284)
41. Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: a case series.
Landy SH
Headache; 2004 Sep; 44(8):762-6. PubMed ID: 15330821
[TBL] [Abstract][Full Text] [Related]
42. [Oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain].
Borgbjerg FM; Rosenberg J
Ugeskr Laeger; 2000 Sep; 162(39):5237-40. PubMed ID: 11043058
[TBL] [Abstract][Full Text] [Related]
43. Intranasal sufentanil for cancer-associated breakthrough pain.
Good P; Jackson K; Brumley D; Ashby M
Palliat Med; 2009 Jan; 23(1):54-8. PubMed ID: 19144765
[TBL] [Abstract][Full Text] [Related]
44. [Breakthrough pain--analysis and therapy. A pilot study of a new drug, transmucosal fentanyl (Actiq)].
Johansson H; Arnér S
Lakartidningen; 2004 Feb; 101(7):552-4. PubMed ID: 15024861
[No Abstract] [Full Text] [Related]
45. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain.
Ashburn MA; Slevin KA; Messina J; Xie F
Anesth Analg; 2011 Mar; 112(3):693-702. PubMed ID: 21304148
[TBL] [Abstract][Full Text] [Related]
46. Managing pain from advanced cancer in the palliative care setting.
Ferrell B; Levy MH; Paice J
Clin J Oncol Nurs; 2008 Aug; 12(4):575-81. PubMed ID: 18676325
[TBL] [Abstract][Full Text] [Related]
47. Recognition and diagnosis of breakthrough pain.
Payne R
Pain Med; 2007; 8 Suppl 1():S3-7. PubMed ID: 17280600
[TBL] [Abstract][Full Text] [Related]
48. Treating cancer-related breakthrough pain: the oral transmucosal route.
Laverty D
Int J Palliat Nurs; 2007 Jul; 13(7):326-31. PubMed ID: 17851376
[TBL] [Abstract][Full Text] [Related]
49. [Management of breakthrough cancer pain].
Sláma O
Klin Onkol; 2013; 26(3):191-4. PubMed ID: 23763322
[TBL] [Abstract][Full Text] [Related]
50. A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain.
Otis J; Rothman M
Curr Med Res Opin; 2006 Aug; 22(8):1493-501. PubMed ID: 16870074
[TBL] [Abstract][Full Text] [Related]
51. Cancer-related breakthrough pain.
Davies AN
Br J Hosp Med (Lond); 2006 Aug; 67(8):414-6. PubMed ID: 16918095
[TBL] [Abstract][Full Text] [Related]
52. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.
Mercadante S
Expert Opin Pharmacother; 2012 Apr; 13(6):873-8. PubMed ID: 22424558
[TBL] [Abstract][Full Text] [Related]
53. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
54. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
55. A review of the pharmacokinetic profile of transmucosal fentanyl formulations.
Moore N; Darwish M; Amores X; Schneid H
Curr Med Res Opin; 2012 Nov; 28(11):1781-90. PubMed ID: 23020252
[TBL] [Abstract][Full Text] [Related]
56. Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology.
Mystakidou K; Tsilika E; Tsiatas M; Vlahos L
Int J Nanomedicine; 2007; 2(1):49-54. PubMed ID: 17722512
[TBL] [Abstract][Full Text] [Related]
57. Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients.
Nalamachu SR; Narayana A; Janka L
Curr Med Res Opin; 2011 Apr; 27(4):751-60. PubMed ID: 21288055
[TBL] [Abstract][Full Text] [Related]
58. Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain.
Núñez-Olarte JM; Alvarez-Jiménez P
J Pain Symptom Manage; 2011 Dec; 42(6):e6-8. PubMed ID: 22048003
[No Abstract] [Full Text] [Related]
59. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain.
Payne R; Coluzzi P; Hart L; Simmonds M; Lyss A; Rauck R; Berris R; Busch MA; Nordbrook E; Loseth DB; Portenoy RK
J Pain Symptom Manage; 2001 Jul; 22(1):575-83. PubMed ID: 11516599
[TBL] [Abstract][Full Text] [Related]
60. Breakthrough pain in chronic non-cancer pain: fact, fiction, or abuse.
Manchikanti L; Singh V; Caraway DL; Benyamin RM
Pain Physician; 2011; 14(2):E103-17. PubMed ID: 21412376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
